Analyst Ratings for BridgeBio Oncology Therapeutics, In (BBOT)
BBOT Rating Summary
BBOT Price Target Summary
- Highest: $32.00 (Leerink Partners)
- Lowest: $20.00 (Morgan Stanley)
- Average: $24.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$24.50 (+135.1%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/10/2026 | Stifel » Updated 3/6/2026 |
Laura Prendergast | New Coverage | Buy (N/A) |
23.00 (N/A) |
10.68 (10.42) |
-2.43% | Details |
| 1/9/2026 | Raymond James | Sean McCutcheon | New Coverage | Outperform (N/A) |
24.00 (N/A) |
13.30 (10.42) |
-21.65% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
